JPWO2021245223A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021245223A5
JPWO2021245223A5 JP2022573504A JP2022573504A JPWO2021245223A5 JP WO2021245223 A5 JPWO2021245223 A5 JP WO2021245223A5 JP 2022573504 A JP2022573504 A JP 2022573504A JP 2022573504 A JP2022573504 A JP 2022573504A JP WO2021245223 A5 JPWO2021245223 A5 JP WO2021245223A5
Authority
JP
Japan
Prior art keywords
botulinum toxin
lines
injection
injected
botulinum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022573504A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529095A (ja
JP2023529095A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/064986 external-priority patent/WO2021245223A1/en
Publication of JP2023529095A publication Critical patent/JP2023529095A/ja
Publication of JPWO2021245223A5 publication Critical patent/JPWO2021245223A5/ja
Publication of JP2023529095A5 publication Critical patent/JP2023529095A5/ja
Pending legal-status Critical Current

Links

JP2022573504A 2020-06-05 2021-06-04 高用量低体積のボツリヌス毒素による顔のシワの治療 Pending JP2023529095A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20178574.8 2020-06-05
EP20178574 2020-06-05
PCT/EP2021/064986 WO2021245223A1 (en) 2020-06-05 2021-06-04 High dose and low volume botulinum toxin treatment of facial wrinkles

Publications (3)

Publication Number Publication Date
JP2023529095A JP2023529095A (ja) 2023-07-07
JPWO2021245223A5 true JPWO2021245223A5 (https=) 2024-06-03
JP2023529095A5 JP2023529095A5 (https=) 2024-06-03

Family

ID=71016459

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573504A Pending JP2023529095A (ja) 2020-06-05 2021-06-04 高用量低体積のボツリヌス毒素による顔のシワの治療

Country Status (13)

Country Link
US (1) US12599550B2 (https=)
EP (2) EP4161562B1 (https=)
JP (1) JP2023529095A (https=)
KR (1) KR20230020961A (https=)
CN (1) CN115666629A (https=)
AU (1) AU2021286196A1 (https=)
BR (1) BR112022023413A2 (https=)
CA (1) CA3177835A1 (https=)
ES (1) ES3013130T3 (https=)
IL (1) IL298399A (https=)
MX (1) MX2022014564A (https=)
TW (1) TW202214211A (https=)
WO (1) WO2021245223A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298399A (en) 2020-06-05 2023-01-01 Merz Pharma Gmbh & Co Kgaa Treatment of facial wrinkles with the botulinum toxin in high dose and low volume
KR20240169045A (ko) * 2022-04-01 2024-12-02 충칭 클라루비스 파마슈티컬 컴퍼니 리미티드 보툴리눔 독소 단백질 조성물, 이의 제조 방법 및 용도
EP4626556A1 (en) * 2022-11-28 2025-10-08 Merz Pharma GmbH & Co. KGaA High concentration botulinum toxin treatment for neck rejuvenation
WO2025231403A1 (en) * 2024-05-03 2025-11-06 Revivity Pharma Corporation Methods of administering and manufacturing toxic compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
BRPI0513850A (pt) 2004-07-26 2008-05-20 Merz Pharma Gmbh & Co Kgaa composição terapêutica com uma neurotoxina botulìnica
EP2072039A1 (en) * 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects
PL2271670T3 (pl) 2008-03-14 2015-05-29 Allergan Inc Testy aktywności serotypu A toksyny botulinowej oparte na immunologii
HUE037509T2 (hu) * 2011-09-29 2018-09-28 Cellsnap Llc Készítmények és eljárások toxigenicitás meghatározására
PL3014267T3 (pl) * 2013-06-28 2019-05-31 Merz Pharma Gmbh & Co Kgaa Środki i sposoby określania aktywności biologicznej polipeptydów neurotoksyny w komórkach
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
SG11202005239YA (en) * 2017-12-04 2020-07-29 Revance Therapeutics Inc Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
IL298399A (en) 2020-06-05 2023-01-01 Merz Pharma Gmbh & Co Kgaa Treatment of facial wrinkles with the botulinum toxin in high dose and low volume

Similar Documents

Publication Publication Date Title
DK1817051T3 (en) A pharmaceutical composition comprising botulinum neurotoxin, a nonionic surfactant, sodium chloride and SUCROSE
FI3481852T3 (fi) Uusi botulinum-neurotoksiini ja sen johdannaisia
EP3570816B1 (en) Stable liquid composition comprising botulinum toxin
CN101917960A (zh) 肉毒杆菌毒素复合物的神经毒成分在减少或预防副作用中的应用
US20170157020A1 (en) Method of treatment of wrinkles using topical chemodenervating agents
CN109562148A (zh) 用色氨酸或酪氨酸稳定的液体神经毒素制剂
CN115666629A (zh) 面部皱纹的高剂量和低体积肉毒毒素治疗
KR101135486B1 (ko) 보툴리눔 에이형 독소의 액상제품
JPWO2021245223A5 (https=)
CN101360509A (zh) 包含几种肉毒杆菌毒素的组合物
HK40085901A (en) High dose and low volume botulinum toxin treatment of facial wrinkles
KR20260035937A (ko) 보툴리눔 독소 단백질 조성물 및 이의 용도
RU2024129879A (ru) Лечение морщин верхней части лица
COBO et al. Botulinum toxin A: treatment of hyperfunctional facial lines
KR20250123101A (ko) 효능 및 효과 지속 기간이 증가된 신경독소 조성물
COURSE The Treatment
Ghasemi Neuromodulators Past, Present, Future BTX Type A, Newer Type E
HK1152863B (en) Pharmaceutical compositions comprising botulinum neurotoxin for use in medicine and cosmetics
HK1102495B (en) Pharmaceutical compositions comprising botulinum neurotoxin, a non ionic surfactant, sodium chloride and sucrose